Phase 1 N=12 AGN-Cogni.Q Acute Dose Safety and Pharmacokinetics Dose-Response in Prostate Cancer Patients
Prostate Cancer
Primary: Cardiac Safety Via Electrocardiography (EKG) — 0; 0; 0; 1 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=8 Pharmacokinetics in Oral and Intranasal Formulations of Zolmitriptan.
Healthy
Primary: Effects of Zolmitriptan on Heart Rate (HR). — 64.4; 71.7 lpm
Phase 1 N=83 Safety, Tolerability, and Pharmacokinetics of Single Doses BI 425809
Healthy
Primary: Number of Participants With Drug-related Adverse Events (AE) — 3; 1; 2; 1 Participants
Phase 1 N=19 Itacitinib in Advanced Hepatocellular Carcinoma
Advanced Hepatocellular Carcinoma
Primary: To Assess the Safety and Tolerability of Itacitinib in Patients With HCC: Adverse Events — 14 Participants
Phase 1 N=58 First in Human Study of M6223
Metastatic Solid Tumors
Primary: Part 1A and 1B: Number of Participants Who Experienced Dose Limiting Toxicities (DLTs) Assessed Using National Cancer Institute (NCI) Common Toxicity Criteria for…
Phase 1 N=24 An Open-Label Study Following Oral Dosing of Seladelpar to Participants With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)
Primary Biliary Cholangitis · Compensated Cirrhosis · Hepatic Impairment
Primary: Part A: Pharmacokinetic (PK) Parameter: Cmax of Seladelpar and Its Metabolites (M1, M2, and M3) — 182.0; 367.7; 359.2; 388.5 nanograms per milliliter (ng/mL)
Phase 1 N=36 Phase 1, Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of an Enterovirus D68-specific Monoclonal Antibody in Healthy Adults
Enterovirus Infection
Primary: Number of Participants Experiencing Solicited Adverse Events (AEs) Through 48 Hours Post-infusion — 7; 4; 3; 3 Participants
Phase 1 N=15 A Study in Healthy Men to Test How Fluconazole Influences the Amount of BI 425809 in the Blood
Healthy
Primary: Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to 215 h Post Administration of BI 425809 (AUC0-215) — 3562.1; 8334.6…
Phase 1 N=94 A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Oral ARN-75039 in Healthy Adult Subjects
Healthy Adult Participants
Primary: Incidence of Treatment-Emergent Adverse Events (TEAEs) — 1; 2; 5; 0 Participants
Phase 1 N=16 A Comparison of the Pharmacokinetic Properties of ARN-75039 Tablets With Excipients to Neat ARN-75039 in Hydroxypropyl Methylcellulose (HPMC) Capsules in Healthy Adult Participants Under Fed Conditions
Healthy Volunteer · Pharmacokinetics After Oral Intake
Primary: AUC0-t — 9450; 8990 h*ng/ml
Phase 1 N=9 Opioid Antagonism in Hypogonadotropic Hypogonadism
Hypogonadotropic Hypogonadism · Low Testosterone
Primary: Average Change in Mean Luteinizing Hormone (LH) Value — 1.571 IU/L
Phase 1 N=10 Comparison of Mechanical Penetration Enhancers on Metvixia Skin Penetration
Healthy
Primary: Mean Fluorescence Levels Measured by Spectrofluorometer Probe at Timepoint T0 (Before Metvixia® Application) — 6.41; 6.37; 6.51; 6.38 Nanometer (nm)
Phase 1 N=76 Phase 1 Study of IPG1094 Safety, Tolerability, and PK in Healthy Participants
Healthy Volunteers
Primary: Adverse Events — 0; 2; 3; 3 Participants
Phase 1 N=8 A Study to Learn About the Medicine (PF-07321332 or Nirmatrelvir/Ritonavir) in Healthy Lactating Women
Healthy Participants
Primary: The Maximum Observed Concentration of Nirmatrelvir in Breast Milk Over the Dosing Interval — 1904 Nanograms / milliliter (ng/mL)
Phase 1 N=15 PI Pembro in Combination With Stereotactic Body Radiotherapy for Liver Metastatic Colorectal Cancer
Colorectal Cancer · Colorectal Adenocarcinoma · Stage IVA Colorectal Cancer
Primary: Recurrence Rate at 1 Year — 6 Participants